GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Epzicom (abacavir/lamivudine)

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons

Epzicom

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
EPZICOM: label restriction versus limited-evidence panel practice

The selected label does not recommend the fixed-dose combination below CrCl 30. NIH describes some panel members retaining full-dose lamivudine there but explicitly states that evidence is insufficient.

Before applying: Preserve the evidence qualification and obtain HIV-specialist or institutional adjudication. Do not present that exception as a new label-approved dose.

Also check: EPZICOM: label restriction versus limited-evidence panel practice

Rxlist source

GlobalRPh RX List - EPZICOM

Product / population
EPZICOM fixed-dose HIV-treatment tablet; not individually adjustable lamivudine.
Renal measure
Estimated creatinine clearance (CrCl), mL/min. The selected subsection does not independently establish an estimating equation.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

The selected RX labeling does not recommend EPZICOM at CrCl <30 mL/min. When lamivudine needs a renal reduction, use individual components rather than an invented fraction or interval for the fixed-dose tablet. This is distinct from the separately stored NIH discussion of selected clinicians continuing full-dose lamivudine despite limited evidence.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/epzicom-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - EPZICOM

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

EPZICOM fixed-dose HIV-treatment tablet; not individually adjustable lamivudine.

Renal method: Estimated creatinine clearance (CrCl), mL/min. The selected subsection does not independently establish an estimating equation.
Retrieved: 2026-09-08

Read local renal resultOpen original reference
Professional guidance

NIH adult ARV table: Abacavir/lamivudine

Adults with HIV; product-specific renal recommendations.

Renal method: CrCl (mL/min), usually Cockcroft-Gault.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

Abacavir / lamivudine - NIH adult HIV guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

NIH adult/adolescent HIV treatment; explicitly qualified fixed-dose-combination exception.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

EPZICOM: label restriction versus limited-evidence panel practice

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

guideline difference

EPZICOM: label restriction versus limited-evidence panel practice

The selected label does not recommend the fixed-dose combination below CrCl 30. NIH describes some panel members retaining full-dose lamivudine there but explicitly states that evidence is insufficient.

How to use this: Preserve the evidence qualification and obtain HIV-specialist or institutional adjudication. Do not present that exception as a new label-approved dose.

GlobalRPh RX List - EPZICOMAbacavir / lamivudine - NIH adult HIV guidance

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - EPZICOMNIH adult ARV table: Abacavir/lamivudineAbacavir / lamivudine - NIH adult HIV guidance
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The original fixed-combination renal cutoff is retained for explicit comparison with current labeling.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/epzicom/

Usual Dosing (Adults)

HIV: one tablet containing abacavir 600 mg plus lamivudine 300 mg once daily.

GRPH-epzicom-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Because EPZICOM is a fixed-dose tablet, the historical source says not to prescribe in patients requiring dose adjustment, including CrCl <50 mL/min, hepatic impairment, or dose-limiting adverse events. Individual EPIVIR Oral Solution and ZIAGEN Oral Solution may be considered.

GRPH-epzicom-02 · Source section: Renal DosingRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - EPZICOM

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · EPZICOM fixed-dose HIV-treatment tablet; not individually adjustable lamivudine.

Renal method: Estimated creatinine clearance (CrCl), mL/min. The selected subsection does not independently establish an estimating equation.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The selected RX labeling does not recommend EPZICOM at CrCl <30 mL/min. When lamivudine needs a renal reduction, use individual components rather than an invented fraction or interval for the fixed-dose tablet. This is distinct from the separately stored NIH discussion of selected clinicians continuing full-dose lamivudine despite limited evidence.

RDM45-rxlist-epzicom-10391176cb-C1 · Source locator: Use in Specific Populations: Renal Impairment, lines 339-341.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/epzicom-drug/
Retrieved
2026-09-08
Renal-function method
Estimated creatinine clearance (CrCl), mL/min. The selected subsection does not independently establish an estimating equation.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
89b11c27048b02c0e84f5ebb7d92b317f0f8d9179973ee265510eeb6c550ed68
Separate professional-source layer

University and professional protocols

Professional

NIH adult ARV table: Abacavir/lamivudine

Open original reference

Open / share this exact local source

NIH ClinicalInfo HIV guidelines · Adults with HIV; product-specific renal recommendations.

Renal method: CrCl (mL/min), usually Cockcroft-Gault.
Source date: Not established
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

NIH dose and renal statement

One tablet daily. FDA-recommended use excludes CrCl <30 mL/min because of lamivudine; individualized full-dose use has insufficient evidence.

epzicom:nih-arv-epzicom-1 · Source locator: Appendix B: Abacavir/lamivudine row

Source identity and provenance
Source
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-renal-hepatic-insufficiency-full
Retrieved
2026-09-05
Renal-function method
CrCl (mL/min), usually Cockcroft-Gault.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
288f00c015703497086221b2058fa2e4a6220f4424c3284396c340ae021de4a5
Professional

Abacavir / lamivudine - NIH adult HIV guidance

Open original reference

Open / share this exact local source

NIH / HHS Adult and Adolescent Antiretroviral Guidelines Panel · NIH adult/adolescent HIV treatment; explicitly qualified fixed-dose-combination exception.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

ABC/3TC is not FDA-recommended below CrCl 30 mL/min because of lamivudine. NIH notes insufficient evidence for or against full-dose lamivudine below 30, although some Panel members retain full-dose therapy to preserve the fixed-dose combination. This is a limited-evidence professional practice, not a new label-approved regimen.

RDM45-professional-epzicom-9335c87ac0-C1 · Source locator: Abacavir/lamivudine row, lines 17-19, with lamivudine footnotes.

Source-specific limits

Selected table review only; full-dose use in the lower band requires specialist/institutional judgment.

Source identity and provenance
Source family
professional_guidance
Source
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-renal-hepatic-insufficiency-full
Retrieved
2026-09-08
Renal-function method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not BSA-indexed laboratory eGFR.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
3d4c13361c64b2032640fe21ee115a1f19d1af1a830b28804ee985df1034f11c

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/epzicom/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
272c8c323384485e25e9792928c82f480910fe18e8739113ade11a242b40daa1
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report